evenfolio

Chemicals · NSE: JUBLINGREA

Jubilant Ingrevia

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
591.50−0.03%

Q2 FY27 earnings call · Guided by management

Call held 27 Oct 2026 · Read the filing on NSEFiling

20–25​%Specialty chemical portfolio growth · Specialty chemicals · multi-yearJain · Q&A · p. 9
25​%EBITDA growth · Specialty chemicals and nutrition · multi-yearJain · Q&A · p. 11
₹400–500​CrAnnual capex · every yearJain · Q&A · p. 9
70​%Utilisation of recent investmentsJain · Q&A · p. 10
M.Cap
₹9,421Cr
P/E
26.9×
1Y return
−13.40%
From 52W high
−25.6%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue1,3941,121+24.4%1,300+7.2%
EBITDA212136+56.7%199+6.7%
EBITDA margin15.2%12.1%+314 bps15.3%-8 bps
PBTProfit before tax14893+59.3%141+5.1%
Net profit11169+60.4%106+5.3%
EPS (₹)7.064.40+60.5%6.68+5.7%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

Revenue growth · Specialty chemicals · long term20-25%Specialty chemicals aspiration: 20% to 25% growth a year on multi-year CAGR basis
Capex · long termRs 400-500 CrkeptCapex of at least INR400 crore to INR500 crore every year maintained

Growth expected across all three business segments in FY2027

Shyam Bhartia · Chairman · p. 4
“We remain confident of sustaining this momentum with growth expected across all three business segments in FY2027.”

Annual guidance kept; company hopes to be closer to the upper end

Deepak Jain · CEO and Managing Director · Q&A · p. 6
“I think we are sticking to our guidance. In fact, we think we should given the strong performance in the first half of the year, we should hopefully be closer to the upper end of the guidance we have given for the year.”

More figures from the call

Zettaone · Acquisitions and new business
60–70​%Zettaone business growth · this year
“Zettaone has delivered a strong growth over the last three years and based on the current momentum, we expect the business to grow by at least 60% to 70% this year.”
Deepak Jain · CEO and Managing Directorp. 6
CDMO · Order book
₹1,500​CrPeak potential revenue of confirmed pipeline · this fiscal year
“but even if I keep the big contract aside, we still have a big pipeline which I mentioned in my opening remarks also, with the peak potential of almost INR1,500 crore plus and at least one third of that we will we will clock in in in this year, in this fiscal year itself”
Deepak Jain · CEO and Managing Director · Q&Ap. 8
Acetic anhydride · Segments
20​%Europe market share · next couple of years
“we have significant share in Europe already in acetic anhydride, let us say high teens close to 20%. Our aspiration has been to double our market share. We feel on the back of this opportunity over the course of next couple of years, we should be able to do that.”
Deepak Jain · CEO and Managing Director · Q&Ap. 7
Consumer / personal care · Segments
7​%Share of overall portfolio · within next few quarters
“So, all of that has started to show a noticeable difference, but it is still at only 7% of our overall portfolio. We are hoping that this slice in our overall pie chart will increase much faster going forward and will hopefully reach double digits within next few quarters.”
Deepak Jain · CEO and Managing Director · Q&Ap. 7
CDMO · Order book
25​moleculesConfirmed molecules in pipeline · coming years
“Overall, we have 25 plus confirmed molecules in our pipeline, which are expected to drive our future growth in coming years.”
Deepak Jain · CEO and Managing Directorp. 5

In short

  1. 01Management is sticking to its annual guidance and hopes to be near the upper end.
  2. 02Agreement signed to buy 40% of Zettaone for INR189 crore; Zettaone expected to grow at least 60% to 70% this year.
  3. 03Confirmed CDMO pipeline excluding the big contract has peak potential of INR1,500 crore plus; at least one third expected this fiscal year.
  4. 04Capex of at least INR400 crore to INR500 crore every year; Gajraula multipurpose plant ready in next few months.
  5. 05Specialty chemicals aspiration is 20% to 25% growth a year on a multi-year CAGR basis.
  6. 06European competitor plant closure: uplift expected from early next calendar year; aim to double Europe acetic anhydride share.
  7. 07Visibility on future volumes of the large CDMO contract expected within next few weeks.

Capex

New multipurpose plant on track for commissioning by year-end

Shyam Bhartia · Chairman · p. 4
“Additionally, our new multipurpose plant remains on track for commissioning by the year-end. This will further strengthen our CDMO and fine chemicals growth roadmap”

Gajraula multipurpose plant ready in next few months; two new plants a year on average

Deepak Jain · CEO and Managing Director · Q&A · p. 9
“On an average, we are creating two new plants, ideally multipurpose plants every year. The Gajraula multipurpose plant will be ready in in next few months itself and we are in the process of conceptualizing couple of other investments.”

Semiconductors: Upcoming R&D and cleanroom facility in Greater Noida for semiconductors

Deepak Jain · CEO and Managing Director · p. 5
“In semiconductors, we continue to see growing inquiries and an expanding application pipeline, supported by our upcoming R&D and cleanroom facility in Greater Noida.”

New plants needed as recent investments reach higher utilisation

Deepak Jain · CEO and Managing Director · Q&A · p. 10
“And hence, we to the earlier question on capex, we need to keep creating new plants, which is what we are doing to enable our incremental growth from here.”

Order book

CDMO: Way forward on large CDMO contract to be disclosed, hopefully within next few weeks

Deepak Jain · CEO and Managing Director · Q&A · p. 7
“We are very close to concluding what the way forward would be and as soon as we have the visibility, we will be able to disclose that to all of you, hopefully within next few weeks.”

CDMO: Full potential including the big contract is close to INR2,000 crore

Deepak Jain · CEO and Managing Director · Q&A · p. 8
“On the back of some of the incremental opportunities that we have secured, that full potential along with the big contract is close to INR2,000 crore”

CDMO: At least 25 plus molecules confirmed in last four quarters

Deepak Jain · CEO and Managing Director · Q&A · p. 11
“if you see in last four quarters itself, we have confirmed at least 25 plus molecules.”

CDMO: Part of this year's new-molecule revenue to come in the next two quarters

Deepak Jain · CEO and Managing Director · Q&A · p. 11
“See, I think of course part of it will come in the subsequent two quarters as well.”

Segments

Specialty chemicals: Specialty chemicals Q2 revenue INR560 crore, up 16%; EBITDA INR140 crore at 25% margin

Deepak Jain · CEO and Managing Director · p. 4
“In specialty chemicals, the business delivered a strong performance with revenue reaching INR560 crore, up 16% year-on-year and 5% sequentially, led by healthy volume growth across fine chemicals and CDMO. We delivered EBITDA of INR140 crore, translating into a strong EBITDA margin of 25%”

Nutrition and health solution: Nutrition and health Q2 revenue INR270 crore, up 50%; EBITDA INR39 crore, margin 15%

Deepak Jain · CEO and Managing Director · p. 5
“INR270 crore, up 50% year-on-year and 11% sequentially. EBITDA increased to INR39 crore, representing growth of 87% year-on-year and 9% sequentially, while margins remained healthy at 15%.”

Chemical intermediates: Chemical intermediates Q2 revenue grew 24% to INR563 crore; EBITDA INR64 crore, up 26%

Deepak Jain · CEO and Managing Director · p. 5
“Segment revenue grew 24% year-on-year and 8% sequentially to INR563 crore. EBITDA rose significantly to INR64 crore, up 26% year-on-year and 13% sequentially, driven by improved realizations across the product portfolio.”

Acetyls: Higher Acetyls volumes anticipated, supported by planned closures in Europe

Shyam Bhartia · Chairman · p. 4
“Within Acetyls in particular, we anticipate higher volumes supported by planned closures in Europe.”

Agro-chemicals: Agro-chemical segment under pressure with muted pricing due to excess capacity in China

Shyam Bhartia · Chairman · p. 4
“The agro-chemical segment remained under pressure with stable volumes but muted pricing, primarily due to excess capacity in China.”

Demand

Europe plant closure uplift expected from early next calendar year; big blip hoped in FY28

Deepak Jain · CEO and Managing Director · Q&A · p. 6
“So, we expect some uplift starting to happen only from early part of next calendar year. How much of that can be captured in this year we will have to see, but we will look at it as a as a multi-year opportunity of course and hope to get a big blip in FY28 from that opportunity.”

Electronics: Electronics manufacturing and design market growing 35%-40% a year

Deepak Jain · CEO and Managing Director · Q&A · p. 8
“The market is growing at 35%, 40% every year.”

Margins and costs

Vitamin B3: Vitamin B3 price decline may linger into Q3; most segments holding price

Deepak Jain · CEO and Managing Director · Q&A · p. 12
“I think by and large most segments are holding up the price. So I am hoping there should not be any negative impact except for maybe vitamin B3 where we have seen some decline in the last few weeks which may linger into Q3.”

Pricing pressure on base pyridine and B3

Deepak Jain · CEO and Managing Director · Q&A · p. 12
“there is some pricing pressure on base pyridine, there is some pricing pressure coming for B3, which are the normal factors which play out in our portfolio every year.”

Acetyls: Acetyls input and utility costs partly offset improved pricing

Shyam Bhartia · Chairman · p. 3
“However, input and utility costs during the quarter partially offset the benefits of improved pricing.”

Pyridine and picolines: Cost optimisation and debottlenecking expected to strengthen pyridine and picolines

Deepak Jain · CEO and Managing Director · p. 5
“Our ongoing cost optimization and capacity debottlenecking initiatives are expected to strengthen performance going forward.”

Vitamin B3: Vitamin B3 pricing generally goes down in Q3

Deepak Jain · CEO and Managing Director · Q&A · p. 12
“If you see for last three years or five years. Q3, generally pricing goes down now in coming the current quarter for vitamin B3.”

Acquisitions and new business

Agreement signed to acquire 40% stake in Zettaone for INR189 crore

Deepak Jain · CEO and Managing Director · p. 6
“I am delighted to share that we have recently signed an agreement to acquire 40% stake in Zettaone with an investment of INR189 crore.”

Zettaone: Zettaone is setting up a new manufacturing facility near Bangalore

Deepak Jain · CEO and Managing Director · p. 6
“The company is also establishing a new manufacturing facility in near Bangalore, which will further support its growth journey.”

Semiconductors: Semiconductor funnel up almost 30% in last few months

Deepak Jain · CEO and Managing Director · Q&A · p. 8
“our semiconductor funnel has already increased by almost 30% in last few months”

Zettaone: Too early to say if Zettaone is a new vertical

Deepak Jain · CEO and Managing Director · Q&A · p. 13
“Yes, it is, too early to answer that. We will see how the base business scales up and, and how the synergies scale up.”

Zettaone: Zettaone shareholders agreement to be concluded soon

Deepak Jain · CEO and Managing Director · p. 6
“The transaction is progressing well and the shareholders agreement will also be concluded soon.”

Risks

CDMO: Large contract counterparty: risk said to be fully protected under agreement

Deepak Jain · CEO and Managing Director · Q&A · p. 10
“we have a very solid agreement as well as understanding with them. Our risk is fully protected as per that arrangement”

Other

Q2 revenue grew 24% and EBITDA 51% year-on-year

Shyam Bhartia · Chairman · p. 3
“We are pleased to report that we continued to sustain strong growth momentum in Q2 with revenue growing 24% year-on-year and EBITDA increasing 51%, reflecting disciplined execution across our businesses.”

H1 revenue grew 25% and EBITDA 44% year-on-year

Shyam Bhartia · Chairman · p. 3
“This momentum was also reflected in our strong first half performance with revenue growing 25% and EBITDA by 44% year-on-year.”

Q2 revenue at all-time high of INR1,394 crore, up 24%; EBITDA up 51%

Deepak Jain · CEO and Managing Director · p. 4
“Revenue reached an all-time high of INR1,394 crore, up 24% year-on-year, supported by stronger realizations and stable volumes. EBITDA rose 51% year-on-”

Q2 PAT increased 60% year-on-year to INR111 crore

Deepak Jain · CEO and Managing Director · p. 4
“year to INR 221 crore, the highest in the last three years, while PAT increased 60% year-on-year to INR111 crore.”

Quarterly EBITDA has more than doubled over the past 3 years

Shyam Bhartia · Chairman · p. 3
“Our quarterly EBITDA has more than doubled over the past 3 years, underscoring the successful execution of our pinnacle strategy and continued focus on disciplined cost management.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools